Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ABT-101

Phase 2Small molecule

AAnbogen Therapeutics, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid Tumor and NSCLCRecruiting

Solid Tumor and NSCLCPhase 2

Recruiting

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Solid Tumor and NSCLC

NCT05532696

Clinical

Trials by Indication[1]

Solid Tumor and NSCLC1 trial

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

Recruiting·AAnbogen Therapeutics, Inc.·Phase 1/2·NCT05532696·61 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ABT-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABT-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABT-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Anbogen Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAnbogen Therapeutics, Inc.

Related News